Skip to main content

Can you take Afamitresgene autoleucel with Hepatitis a pediatric vaccine?

1 drug interaction and 5 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

hepatitis A pediatric vaccine afamitresgene autoleucel

Applies to: hepatitis a pediatric vaccine and afamitresgene autoleucel

If you are currently being treated or have recently been treated with afamitresgene autoleucel, you should let your doctor know before receiving hepatitis A pediatric vaccine. Depending on the dose and length of time you have been on afamitresgene autoleucel, you may have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of afamitresgene autoleucel therapy. If you have recently been vaccinated with hepatitis A pediatric vaccine, your doctor may choose to postpone treatment with afamitresgene autoleucel for a couple of weeks or more. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Disease interactions

5 potential interactions Applies to: 4 conditions, including Liver Disease, Infection, Immunodeficiency, and Renal Dysfunction.

Immunodeficiency

Moderate:

hepatitis a pediatric vaccine

hepatitis A pediatric vaccine has a moderate potential interaction with Immunodeficiency.

The use of hepatitis A vaccine in immunocompromised persons, including individuals receiving immunosuppressive therapy, may result in diminished immune response to the vaccine and these patients may not be protected against hepatitis A virus. Monitoring is recommended when vaccinating these patients.

Infection

Moderate:

afamitresgene autoleucel

Afamitresgene autoleucel has a moderate potential interaction with Infection.

Afamitresgene autoleucel is not recommended in patients with active infections. Additionally, this drug may cause viral reactivation. Patients should be screened for presence of viral and infectious agents (e.g., Epstein-Barr Virus, Cytomegalovirus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus) if clinically indicated. Monitor for signs and symptoms of infection before and after treatment. Consider antiviral therapy to prevent viral reactivation per local guidelines.

Liver Disease

Moderate:

afamitresgene autoleucel

Afamitresgene autoleucel has a moderate potential interaction with Liver Disease.

Afamitresgene autoleucel has not been studied in patients with any degree of hepatic impairment.

Moderate:

hepatitis a pediatric vaccine

hepatitis A pediatric vaccine has a moderate potential interaction with Liver Disease.

The use of hepatitis A vaccine in patients with chronic liver disease may result in lower antibody response. Care should be exercised when using this agent in patients with liver disease.

Renal Dysfunction

Moderate:

afamitresgene autoleucel

Afamitresgene autoleucel has a moderate potential interaction with Renal Dysfunction.

Afamitresgene autoleucel has not been studied in patients with any degree of renal impairment.

More resources

afamitresgene autoleucel

A total of 200 drugs are known to interact with afamitresgene autoleucel.

hepatitis a pediatric vaccine

A total of 340 drugs are known to interact with hepatitis a pediatric vaccine.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.